Overview

PerkinElmer announced its agreement to acquire Tulip Diagnostics on January 9, 2017.

PerkinElmer is a global leader committed to innovating for a healthier world through solving critical issues especially impacting the diagnostics, discovery and analytical solutions markets.

Tulip Diagnostics is one of India’s largest domestic providers of in-vitro diagnostic reagents, kits and instruments to an expansive customer base of diagnostic labs and government and private healthcare facilities.

Significance

The deal supports PerkinElmer’s growth in emerging market diagnostics, which is an attractive end market and key area of focus.

The acquisition also expands PerkinElmer’s infectious disease screening menu and capabilities.

Tulip’s product portfolio, channel access, and broad footprint will accelerate PerkinElmer’s growth in India and around the world.

Crosstree’s Role

Financial advisor to Tulip Group.